Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot109310.32687/0869-866X-2022-30-6-1211-1219Научная статьяThe evolution of personalized medicine: publications reviewRykovM. Yu.wordex2006@rambler.ruN. A. Semashko National Research Institute of Public Health151220223061211121921122022Copyright © 2022,2022The personalized medicine is based on suggestion that each person has unique characteristics at molecular, physiological, ecological and behavioral levels. In case of development of disease one is to be treated considering these unique characteristics. This belief was to some extent confirmed by application of such newest technologies as DNA sequencing, proteomics, imaging protocols and application of wireless health monitoring devices which established large inter-individual differences.The purpose of the study was to summarize and systematize the results of publications on personalized medicine and its development.The search for scientific articles was carried out, including the published in peer-reviewed journals indexed in Pubmed, WoS, Scopus and RSCI. The review covers 49 articles considering new technologies that make possible the personalized medicine possible, new experience, modes of verification and application of individualized medications as well as potential means of treating people with fertility problems and infertility.The individualization of medical practice in particular cases is probably inevitable all the more the individual approach to patient becomes more effective and cost-effective. The accessibility of modern biomedical technologies, emergence of wireless monitoring devices allows to implement “personalized” approach to early, subclinical diagnostic, individualization of treatment in order to obtain maximal efficiency and minimal toxicity of therapy, prevention of relapse of disease and its prevention. The technology of cell avatars will permit to prognose development of diseases and, possibly, life expectancy too. The personalized approach in reproductology based on genetic research will permit to eliminate a number of hereditary, orphan diseases in XXI century the same way as studies in immunology and development of vaccines made it possible to eliminate black smallpox in XX century.Conclusion. The future challenges consist not only in looking for new manifold modes of characterizing patient, but also in personalization of therapy, development of individual medication and disease prevention schemes. It is presumably that applying more relevant models based on human cell cultures will allow not only to study pharmacodynamics of medications, but also to implement personalized selection of medication therapy, considering nature of disease and comorbid background of patient.personalized medicinereviewbiomarkerspatientmonitoringgenomicsперсонифицированная медицинаобзорбиомаркерымониторинг пациентовгеномик1.Schork N. J. Time for one-person trials. Personal. Med. 2015;520(7549):609-11.2.Lillie E. O., Patay B., Diamant J., Issell B., Topol E. J., Schork N. J. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personal. Med. 2011;8(2):161-73.3.Duan N., Kravitz R. L., Schmid C. H. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J. Clin. Epidemiol. 2013;66(8 Suppl):S21-8.4.Scuffham P. A., Nikles J., Mitchell G. K., Yelland M. J., Vine N., Poulos C. J., Pillans P. I., Bashford G., del Mar C., Schluter P. J., Glasziou P. Using N-of-1 trials to improve patient management and save costs. J. Gen.Intern. Med. 2010;25(9):906-13.5.Daza E. J. Causal analysis of self-tracked time series data using a counterfactual framework for N-of-1 trials. Methods Inf. Med. 2018;57(1):e10-e21.6.Swan M. The quantified self: fundamental disruption in big data science and biological discovery. Big Data. 2018;1(2):85-99.7.Biankin A. V., Piantadosi S., Hollingsworth S. J. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015;526(7573):361-70.8.Simon R., Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 2013;12(5):358-69.9.Chen Y., Elenee Argentinis J. D., Weber G. IBM Watson: How cognitive computing can be applied to big data challenges in life sciences research. Clin. Ther. 2016;38(4):688-701.10.Klasnja P., Hekler E. B., Shiffman S., Boruvka A., Almirall D., Tewari A., Murphy S. Microrandomized trials: An experimental design for developing just-in-time adaptive interventions. Health Psychol. 2015;34S:1220-8.11.Laber E. B., Lizotte D. J., Qian M., Pelham W. E., Murphy S. A. Dynamic treatment regimens: technical challenges and applications. Electron. J. Stat. 2014;8(1):1225-72.12.Chakraborty B., Murphy S. A. Dynamic Treatment Regimes. Ann. Rev. Stat. Appl. 2014;1:447-64.13.Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76.14.Beltrao-Braga P. C., Pignatari G. C., Russo F. B., Fernandes I. R., Muotri A. R. In-a-dish: induced pluripotent stem cells as a novel model for human diseases. Part A. J.Int. Soc. Analyt. Cytol. 2013;83(1):11-7.15.Sayed N., Liu C., Wu J. C. Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J. Am. Coll. Cardiol. 2016;67(18):2161-76.16.Wu J., Izpisua Belmonte J. C. Stem Cells: A renaissance in human biology research. Cell. 2016;165(7):1572-85.17.Uppada V., Gokara M., Rasineni G. K. Diagnosis and therapy with CRISPR advanced CRISPR based tools for point of care diagnostics and early therapies. Gene. 2018 May 20;656:22-9.18.Ho B. X., Pek N. M. Q., Soh B. S. Disease modeling using 3D organoids derived from human induced pluripotent stem cells.Int. J. Mol. Sci. 2018 Mar 21;19(4):936.19.Aboulkheyr Es. H., Montazeri L., Aref A. R., Vosough M., Baharvand H. Personalized cancer medicine: an organoid approach. Trends Biotechnol. 2018;36(4):358-71.20.Crystal A. S., Shaw A. T., Sequist L. V., Friboulet L., Niederst M. J., Lockerman E. L., Frias R. L., Gainor J. F., Amzallag A., Greninger P., Lee D., Kalsy A., Gomez-Garaballo M., Elamine L., Howe E., Hur W., Lifshits E., Robinson H. E., Katayama R., Faber A. C., Award M. M., Ramaswamy S., Mino-Kenudson M., Iafrate A. J., Benes C. H., Engelman J. A. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480-6.21.Jonas O., Landry H. M., Fuller J. E., Santini J. T. Jr, Baselga J., Tepper R. I. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci. Transl. Med. 2015;7(284):284ra57.22.Klinghoffer R. A., Bahrami S. B., Hatton B. A., Frazier J. P., Moreno-Gonzalez A., Strand A. D., Kerwin W. S., Casalini J. R., Thirstrup D. J., You S., Morris S. M., Watts K. L., Veiseh M., Grenley M. O., Trtyak I., Dey J., Carleton M., Beirne E., Pedro K. D., Ditzler S. H., Girard E. J., Deckwerth T. L., Bertout J. A., Meleo K. A., Filvaroff E. H., Chopra R., Press O. W., Olson J. M. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci. Transl. Med. 2015;7(284):284ra58.23.Robinton D. A., Daley G. Q. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481(7381):295-30.24.Appelboom G., Camacho E., Abraham M. E., Bruce S. S., Dumont E. L., Zacharia B. E. Smart wearable body sensors for patient self-assessment and monitoring. Arch. Pub. Health. 2014;72(1):28.25.Swan M. The quantified self: fundamental disruption in big data science and biological discovery. Big Data. 2013;1(2):85-99.26.Schork N. J., Nazor K.Integrated genomic medicine: a paradigm for rare diseases and beyond. Adv. Genet. 2017;97:81-113.27.Worthey E. A., Mayer A. N., Syverson G. D., Helbling D., Bonacci B. B., Decker B., Serpe J. M. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. J. Med. Genet. 2011;13(3):255-62.28.Bainbridge M. N., Wiszniewski W., Murdock D. R., Friedman J., Gonzaga-Jauregui C., Newsham I. Whole-genome sequencing for optimized patient management. Sci. Transl. Med. 2011;3(87):87re3.29.O’Rawe J. A., Fang H., Rynearson S., Robison R., Kiruluta E. S., Higgins G.Integrating precision medicine in the study and clinical treatment of a severely mentally ill person. Peer J. 2013;1:e177.30.Chen Y. Z., Friedman J. R., Chen D. H., Chan G. C., Bloss C. S., Hisama F. M. Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. Ann. Neurol. 2014;75(4):542-9.31.Wartman L. D. A case of me: clinical cancer sequencing and the future of precision medicine. Cold Spring Harbour Mol. Case Stud. 2015;1(1): a000349.32.Chen R., Mias G. I., Li-Pook-Than J., Jiang L., Lam H. Y., Chen R., Miriami E. Personal omics profiling reveals dynamic molecular and medical phenotypes. Ann. Neurol. 2012;148(6):1293-307.33.Smarr L. Quantifying your body: a how-to guide from a systems biology perspective. J. Biotechnol. 2012;7(8):980-91.34.David L. A., Materna A. C., Friedman J., Campos-Baptista M. I., Blackburn M. C., Perrotta A., Erdman S. E., Alm E. J. Host lifestyle affects human microbiota on daily timescales. Genome Biol. 2014;15(7):R89.35.Forsdyke D. R. Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker. Biomed Res. 2015;8:227. doi: 10.7287/peerj.preprints.144v236.Trammell S. A., Schmidt M. S., Weidemann B. J., Redpath P., Jaksch F., Dellinger R. W. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat.Commun. 2016;7:12948.37.Schork N. J. Genetic parts to a preventive medicine whole. Genome Med. 2013;5(6):54.38.Patel C. J., Sivadas A., Tabassum R., Preeprem T., Zhao J., Arafat D. Whole genome sequencing in support of wellness and health maintenance. Genome Med. 2013;5(6):58.39.Sverdlov O., van Dam J., Hannesdottir K., Thornton-Wells T. Digital Therapeutics: An Integral Component of Digital Innovation in Drug Development. Clin. Pharmacol. Ther. 2018 Jul;104(1):72-80.40.Kaner E. F., Beyer F. R., Garnett C., Crane D., Brown J., Muirhead C. Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community-dwelling populations. Cochrane Database Syst. Rev. 2017 Sep 25;9(9):CD011479.41.Iacoviello B. M., Steinerman J. R., Klein D. B., Silver T. L., Berger A. G., Luo S. X. Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial Evaluation. J. Med.Internet Res. 2017;5(4):e56.42.Jungheim E. S., Carson K. R. Leveraging real-world data to move toward more personalized fertility treatment. Fertil. Steril. 2018;109(4):608-9.43.Van Dijk M. R., Koster M. P. H., Willemsen S. P., Huijgen N. A., Laven J. S. E., Steegers-Theunissen R. P. M. Healthy preconception nutrition and lifestyle using personalized mobile health coaching is associated with enhanced pregnancy chance. Reproduct. Biomed. 2017;35(4):453-60.44.Yurttas Beim P., Parfitt D. E., Tan L., Sugarman E. A., Hu-Seliger T., Clementi C. At the dawn of personalized reproductive medicine: opportunities and challenges with incorporating multigene panel testing into fertility care. J. Assist. Reproduct. Genet. 2017;34(12):1573-6.45.DeAngelis A. M., Roy-O’Reilly M., Rodriguez A. Genetic alterations affecting cholesterol metabolism and human fertility. Biol. Reproduct. 2014;91(5):117.46.Jungheim E. S., Meyer M. F., Broughton D. E. Best practices for controlled ovarian stimulation in in vitro fertilization. Semin. Reproduct. Med. 2015;33(2):77-82.47.Tao T., Del Valle A. Human oocyte and ovarian tissue cryopreservation and its application. J. Assist. Reproduct. Genet. 2008;25(7):287-96.48.Geel T. M., Ruiters M. H. J, Cool R. H., Halby L., Voshart D. C., Andrade Ruiz L. The past and presence of gene targeting: from chemicals and DNA via proteins to RNA. Philos. Transact. Royal Soc. B: Biol. Sci. 2018;373(1748):20170077.49.Nagamatsu G., Hayashi K. Stem cells, in vitro gametogenesis and male fertility. Reproduction. 2017;154(6):F79-F91.